Gram, Hermann (2016) Preclinical Characterization and Clinical Development of ILARIS® (canakinumab) for the Treatment of Autoinflammatory Diseases. Chemical Biology. ISSN 13675931

Abstract

Interleukin-1beta (IL-1) is a pro-inflammatory cytokine which is part of the first line innate response in vertebrates and is induced in injury, infection, and immunity. While temporally limited induction of IL-1 is believed to protect the organisms against traumatic or infectious insults, its aberrant expression in chronic inflammation is detrimental. Therefore, pharmacological neutralization of IL-1 in chronic inflammatory diseases is a meaningful strategy to treat inflammation and to alleviate respective clinical symptoms in man. Canakinumab is a high-affinity human monoclonal antibody designed to target human IL-1 in inflammatory diseases. Indeed, canakinumab has shown excellent efficacy in rare genetic autoinflammatory diseases or pathological conditions associated with aberrant production of IL-1. This review focusses on the molecular and clinical mode of action and pharmaceutical development of canakinumab in (auto)inflammatory diseases.

Item Type:	Article
Date Deposited:	26 Apr 2016 23:45
Last Modified:	26 Apr 2016 23:45
URI:	https://oak.novartis.com/id/eprint/26829